

**AMENDMENT AND RESPONSE TO OFFICE ACTION**  
**U.S.S.N. 10/522,595**


**Amendment to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1 -46. (Cancelled)

47. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form  $-C(R_5)=N-$ ;

Y is  $-C(R_5)-$  and taken together with the carbon atom bearing the phenyl group forms a double bond and R<sub>1</sub> is absent;

Y' is  $-N(R_5)-$ ;

Z forms a covalent single bond between X' and Y';

R<sub>2</sub> and R<sub>4</sub> are independently selected from hydrogen and C<sub>1-3</sub>alkyl;

R<sub>3</sub> is selected from C<sub>1-3</sub>alkyl and (A)<sub>m</sub>R<sub>12</sub>;

$-C(R_5)-$  is selected from  $-C(H)-$  and  $-C(C_{1-2} \text{alkyl})-$ ;

$-N(R_5)-$  is selected from  $-N(H)-$  and  $-N(C_{2-20} \text{alkyl})-$ ;


m is 0;

**AMENDMENT AND RESPONSE TO OFFICE ACTION**  
**U.S.S.N. 10/522,595**

$R_{12}$  is selected from the group consisting of OH, SH, NH<sub>2</sub>, halo, NO<sub>2</sub>, C(R<sub>17</sub>)<sub>3</sub>, OC(R<sub>17</sub>)<sub>3</sub> and CN; and

$R_{17}$  is independently selected from hydrogen and halogen; and  
wherein each alkyl may be optionally substituted.

48. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form -C(R<sub>5</sub>)=N-;

Y is -C(R<sub>5</sub>)- and taken together with the carbon atom bearing the phenyl group forms a double bond and R<sub>1</sub> is absent;

Y' is -N(R<sub>5</sub>)-;

Z forms a covalent single bond between X' and Y';

R<sub>2</sub> and R<sub>4</sub> are independently selected from hydrogen and C<sub>1-3</sub>alkyl;

R<sub>3</sub> is selected from C<sub>1-3</sub>alkyl and (A)<sub>m</sub>R<sub>12</sub>;

-C(R<sub>5</sub>)- is selected from -C(H)- and -C(C<sub>1-20</sub>alkyl)-;

-N(R<sub>5</sub>)- is selected from -N(alkyl)- wherein alkyl is selected from the group consisting of ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

**AMENDMENT AND RESPONSE TO OFFICE ACTION**  
**U.S.S.N. 10/522,595**

m is 0;

R<sub>12</sub> is selected from the group consisting of OH, SH, NH<sub>2</sub>, halo, NO<sub>2</sub>, C(R<sub>17</sub>)<sub>3</sub>, OC(R<sub>17</sub>)<sub>3</sub> and CN;

R<sub>17</sub> is independently selected from hydrogen and halogen; and  
wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is -CH-; and

X is -CH-.

50. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is OC(R<sub>17</sub>)<sub>3</sub>.

51. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is C<sub>1-3</sub>alkyl.

52. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is -CH<sub>3</sub> or -OCH<sub>3</sub>.

53. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R<sub>5</sub>)- is N(3-methylbutyl).

54. (Previously presented) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (Previously presented) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (Previously presented) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (Previously presented) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.